Compare BTTC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTTC | TVRD |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 37.3M |
| IPO Year | N/A | N/A |
| Metric | BTTC | TVRD |
|---|---|---|
| Price | $1.71 | $4.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 142.3K | ★ 143.4K |
| Earning Date | 01-01-0001 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $2,719,480.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.36 | ★ N/A |
| Revenue Growth | ★ 2.04 | N/A |
| 52 Week Low | $1.51 | $3.74 |
| 52 Week High | $39.00 | $43.65 |
| Indicator | BTTC | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.14 |
| Support Level | N/A | $3.87 |
| Resistance Level | N/A | $4.75 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 0.00 | 81.63 |
Black Titan Corp is engaged in software implementation and training. It provides consulting services and Human Resource and Payroll solutions.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.